

Wound Bed Preparation

Moist Wound Healing

Moist Wound Healing

Patient Assessment

Wound Assessment

D

Wound Etiology

I

M

Patient Centered Concerns

E

Debridement

Infection / Inflammation

Moisture Management

Edge

Apply ActiGraft after adequate wound debridement.

ActiGraft can be used in patients that cannot undergo sharp debridement due to pain or limited blood supply and in wounds with tunneling or undermining where the entire wound bed cannot be visualized.

ActiGraft may be used in wounds with exposed vital structures (ie. bone, tendon, muscle) to accelerate macrophages (proinflammatory to anti-inflammatory) and serve as a barrier to bacterial ingress.

ActiGraft creates a moist wound healing environment.

Moisture management of ActiGraft aids in the recruitment of substrates, cells and growth factors that assist in transitioning from a chronic to acute environment and stimulates angiogenesis.


ActiGraft supports wound contraction.

ActiGraft acts as a sealant to mitigate periwound bacteria invasion.

CASE ONE



CASE TWO



Compression

Moist Wound Healing


Moist Wound Healing

Achieve the best possible outcome in the shortest amount of time with ActiGraft


IN ONLY 3 WEEKS....

ActiGraft demonstrated **significant wound area reduction** in the following wound types¹:


Trauma Wounds




Surgical Wounds



Diabetic Foot Ulcers



Pressure Injuries



Percent of registry patients demonstrating at least a 25% area reduction (PAR) within 3 weeks after the initial application.¹

Case Studies

PRESSURE INJURY

64 YEARS OLD / WOUND 5 WEEKS OLD


96% Wound Reduction in 1 Week with 1 ActiGraft Application



DIABETIC FOOT ULCER

37 YEARS OLD / WOUND 28 WEEKS OLD

100% Wound Reduction in 3 Weeks with 2 ActiGraft Applications



PRESSURE INJURY WITH EXPOSED BONE

57 YEARS OLD / WOUND 4 WEEKS OLD

100% Wound Reduction in 23 Weeks with 11 ActiGraft Applications



¹RedDress. (n.d.). Safety and efficacy of actigraft treatment in wound care in medical centers - full text view. Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers. <https://clinicaltrials.gov/ct2/show/NCT04699305?term=reddress&draw=2&rank=5>
Snyder et al Adv Skin Wound Care 2016;29:205-215

Vallejo L, Achterberg J. Uso de una matriz autóloga en el tratamiento de úlceras de pie diabético, con espectroscopia de infrarrojo cercano y medidor de pH dérmico. J Wound Care. 2020 Nov 1;29(LatAm sup 3):24-31. doi: 10.12968/jowc.2020.29.LatAm_sup_3.24. PMID: 33249991.
Ozker E, Meng CW. The use of Actigraft, an autologous skin graft, in the treatment of complex diabetes foot ulcer. Ann Rev Resear. 2021; 6(2): ARR.MS.ID.555685. DOI: 10.19080/ARR.2021.06.555685

Macrae FL, Duval C, Papareddy P, Baker SR, Yuldasheva N, Kearney KJ, McPherson HR, Asquith N, Konings J, Casini A, Degen JL, Connell SD, Philippou H, Wolberg AS, Herwaldt H, Ariens RA. A fibrin biofilm covers blood clots and protects from microbial invasion. J Clin Invest. 2018 Aug 1;128(8):3356-3368. doi: 10.1172/JCI98734. Epub 2018 Jun 25. PMID: 29723165. PMCID: PMC6063501.

Snyder RJ, Lantis J, Kirsner RS, Shah V, Molyneux M, Carter MJ. Macrophages: A review of their role in wound healing and their therapeutic use. Wound Repair Regen. 2016 Jul;24(4):613-29. doi: 10.1111/wrr.12444. Epub 2016 Jun 14. PMID: 27196106.

Gurevich M, Wahab N, Wachuku C, Ead KJ, Snyder RJ. ActiGraft Treatment in Complex Wounds with Exposed Structure - A Case Series. Ann Rev Resear. 2021; 7(1):555701. DOI: 10.19080/ARR.2021.07.555701

RedDress

www.reddressmedical.com